Candidemia en Colombia

Jorge Alberto Cortés, José Franklin Ruiz, Lizeth Natalia Melgarejo-Moreno, Elkin V. Lemos, .

Palabras clave: candidiasis, candidemia, unidad de cuidados intensivos, micosis, infecciones fúngicas invasivas, candidiasis invasiva, Colombia

Resumen

En Colombia, especialmente en las unidades de cuidados intensivos, la candidemia es una causa frecuente de infección del torrente sanguíneo y representa el 88 % de las infecciones fúngicas en pacientes hospitalizados, con una mortalidad entre 36 y 78 %. Su incidencia en Colombia es mayor a la reportada en los países desarrollados e, incluso, en otros países de Latinoamérica. Para su manejo deben considerarse los factores de riesgo del paciente, luego valorar las características clínicas y, finalmente, hacer los estudios microbiológicos y, si es necesario, pruebas moleculares.
En general, las guías estadounidenses, latinoamericanas y europeas recomiendan las equinocandinas como el tratamiento de primera línea de la candidemia y difieren en el uso de fluconazol dependiendo de la ‘evidencia’, la gravedad de la enfermedad, la exposición previa a los azoles y la prevalencia de Candida no albicans. Dada su gran incidencia en nuestro país, asociada con una elevada mortalidad, esta infección debe buscarse sistemáticamente en pacientes con factores de riesgo, con el fin de iniciar oportunamente el tratamiento antifúngico.

 

Descargas

Los datos de descargas todavía no están disponibles.

Referencias bibliográficas

Cortés JA, Reyes P, Gómez CH, Cuervo SI, Rivas P, Casas CA, et al. Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogotá, Colombia. Braz J Infect Dis. 2014;18:631-7. https://doi.org/10.1016/j.bjid.2014.06.009

Nucci M, Thompson-Moya L, Guzmán-Blanco M, Tiraboschi IN, Cortés JA, Echevarría J, et al. Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network. Rev Iberoam Micol. 2013;30:179-88. https://doi.org/10.1016/j.riam.2013.05.007

Zuluaga-Rodríguez A, De Bedout-Gómez C, Agudelo-Restrepo C, Hurtado-Parra H, Arango-Arteaga M, Restrepo-Moreno A, et al. Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001-2007). Rev Iberoam Micol. 2010;27:125-9. https://doi.org/10.1016/j.riam.2010.04.001

Cortés JA, Reyes P, Gómez C, Buitrago G, Leal AL y Group G. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol. 2011;28:74-8. https://doi.org/10.1016/j.riam.2010.12.002

Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortés J, Zurita J, et al. Epidemiology of candidemia in Latin America: A laboratory-based survey. PLoS ONE. 2013;8:e59373. https://doi.org/10.1371/journal.pone.0059373

Berrío I, Maldonado N, De Bedout C, Arango K, Cano LE, Valencia Y, et al. Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia. J Glob Antimicrob Resist. 2018;13:254-60. https://doi.org/10.1016/j.jgar.2017.11.010

Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: How to approach, how to treat. Molecules. 2014;19:1085-119. https://doi.org/10.3390/molecules19011085

Scudeller L, Viscoli C, Menichetti F, del Bono V, Cristini F, Tascini C, et al. An Italian consensus for invasive candidiasis management (ITALIC). Infection. 2014;42:263-79. https://doi.org/10.1007/s15010-013-0558-0

Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3:772-85. https://doi.org/10.1016/S1473-3099(03)00831-4

Cortés JA, Corrales IF. Invasive candidiasis: Epidemiology and risk factors in fungal infection. Londres: Intech Open; 2019:33-46. https://doi.org/10.5772/intechopen.81813

Ortiz-Ruiz G, Osorio J, Valderrama S, Álvarez D, Elias-Díaz R, Calderón J, et al. Risk factors for candidemia in non-neutropenic critical patients in Colombia. Med Intensiva. 2016;40:139-44. https://doi.org/10.1016/j.medin.2015.08.001

De Bedout C, Gómez B. Candida y candidiasis invasora: un reto continuo para su diagnóstico temprano. Infectio. 2010;14:s159-71. https://doi.org/10.1016/S0123-9392(10)70133-8

Orozco P, Cortés J, Parra C. Colonización por levaduras en recién nacidos y personal de salud en la unidad de cuidados intensivos neonatales de un hospital universitario en Bogotá, Colombia. Rev Iberoam Micol. 2009;26:108-11 https://doi.org/10.1016/S1130-1406(09)70020-8

Díaz-Granados CA, Martínez A, Deaza C, Valderrama S. An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogotá, Colombia. Braz J Infect Dis. 2008;12:390-4.

Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. Molecular epidemiology of candidemia: Evidence of clusters of smoldering nosocomial infections. Clin Infect Dis. 2008;47:e17-24. https://doi.org/10.1086/589298

Desai JV, Mitchell AP. Candida albicans biofilm development and its genetic control. Microbiol Spectr. 2015;3(3):MB-0005-2014. https://doi.org/10.1128/microbiolspec.MB-0005-2014

Cortés JA, Jaimes JA, Leal AL. Incidencia y prevalencia de candidemia en pacientes críticamente enfermos en Colombia. Rev Chil Infectol. 2013;30:599-604. https://doi.org/10.4067/S0716-10182013000600004

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134-40. https://doi.org/10.1093/cid/ciw691

Parra-Giraldo CM, Valderrama SL, Cortés-Fraile G, Garzón JR, Ariza BE, Morio F, et al. First report of sporadic cases of Candida auris in Colombia. Int J Infect Dis. 2018;69:63-7. https://doi.org/10.1016/j.ijid.2018.01.034

Escandón P, Chow NA, Cáceres DH, Gade L, Berkow EL, Armstrong P, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis. 2019;68:15-21. https://doi.org/10.1093/cid/ciy411

Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:162-4. https://doi.org/10.3201/eid2301.161497

Motoa G, Muñoz JS, Oñate J, Pallares CJ, Hernández C, Villegas MV. Epidemiology of Candida isolates from intensive care units in Colombia from 2010 to 2013. Rev Iberoam Micol. 2017;34:17-22. https://doi.org/10.1016/j.riam.2016.02.006

Thomaz DY, de Almeida JN Jr, Lima GM, Nunes MO, Camargo CH, Grenfell RC, et al. An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol. 2018;9:2997. https://doi.org/10.3389/fmicb.2018.02997

Cortés JA, Prada G. Protocolo de estudio y manejo de pacientes con candidiasis sistémica en adultos. Infectio. 2012;16:118-22. https://doi.org/10.1016/S0123-9392(12)70037-1

Ahmadi A, Ardehali SH, Beigmohammadi MT, Hajiabdolbaghi M, Hashemian SM, Kouchek M, et al. Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013. JRSM Open. 2014;5:2042533313517689. https://doi.org/10.1177/2042533313517689

Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35. https://doi.org/10.1086/596757

Díaz J, Urrego J, Moreno J, Huérfano C, Prieto V. Análisis de costo-efectividad de anidulafungina en el tratamiento de la candidiasis invasiva en Colombia. Value Health. 2015;18:A870. https://doi.org/10.1016/j.jval.2015.09.010

Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: An autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40-6. https://doi.org/10.1046/j.1365-2141.2002.03414.x

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl.7):19-37. https://doi.org/10.1111/1469-0691.12039

León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med. 2009;37:1624-33. https://doi.org/10.1097/CCM.0b013e31819daa14

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vázquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. Clin Infect Dis. 2015;60:892-9. https://doi.org/10.1093/cid/ciu959

Berdal JE, Haagensen R, Ranheim T, Bjornholt JV. Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. PLoS ONE. 2014;9:e103916. https://doi.org/10.1371/journal.pone.0103916

Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006;43:25-31. https://doi.org/10.1086/504810

Aguado JM, Ruiz-Camps I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin. 2011;29:345-61. https://doi.org/10.1016/j.eimc.2011.01.008

Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17(Suppl.5):1-12. https://doi.org/10.1111/j.1469-0691.2011.03615.x

Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, García CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: Frequency, natural history, and etiology. Medicine (Baltimore). 2003;82:187-202. https://doi.org/10.1097/01.md.0000076008.64510.f1

Centers for Disease Control and Prevention. Invasive candidiasis. Fecha de consulta: 31 marzo de 2018. Disponible en: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/index.html

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50. https://doi.org/10.1093/cid/civ933

Oñate J, Rivas J, Pallares C, Saavedra C, Martínez E, Coronell W, et al. Colombian consensus on the diagnosis, treatment, and prevention of Candida spp. disease in children and adults. Infectio. 2019;23:271-304.

Cortés JA, Russi JA. Equinocandinas. Rev Chil Infectol. 2011;28:529-36. https://doi.org/10.4067/S0716-10182011000700004

Marcos-Zambrano LJ, Gómez-Perosanz M, Escribano P, Zaragoza O, Bouza E, Guinea J. Biofilm production and antibiofilm activity of echinocandins and liposomal amphotericin B in echinocandin-resistant yeast species. Antimicrob Agents Chemother. 2016;60:3579-86. https://doi.org/10.1128/AAC.03065-15

Marcos-Zambrano LJ, Escribano P, Bouza E, Guinea J. Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms. J Antimicrob Chemother. 2016;71:2498-501. https://doi.org/10.1093/jac/dkw162

Colombo AL, Guimaraes T, Camargo LF, Richtmann R, Queiroz-Telles F, Salles MJ, et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis. 2013;17:283-312.https://doi.org/10.1016/j.bjid.2013.02.001

Auzinger G, Playford EG, Graham CN, Knox HN, Weinstein D, Kantecki M, et al. Costeffectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC Infect Dis. 2015;15:463. https://doi.org/10.1186/s12879-015-1143-1

Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-22. https://doi.org/10.1093/cid/cis021

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93. https://doi.org/10.1086/520980

Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32:637-48. https://doi.org/10.1016/j.clinthera.2010.04.005

Yan T, Li SL, Wang DX. Comparison between micafungin and caspofungin for the empirical treatment of severe intra-abdominal infections in surgical intensive care patients. Zhonghua Yi Xue Za Zhi. 2016;96:2301-6. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.29.004

Botero MC, Puentes-Herrera M, Cortés JA. Formas lipídicas de anfotericina. Rev Chil Infectol. 2014;31:518-27. https://doi.org/10.4067/S0716-10182014000500002

Cortés JA, Soto R, Ãlvarez CA, Buitrago G, Camargo RD, Cataño JC, et al. Consenso de uso de antimicrobianos en pacientes críticamente enfermos con falla renal o en riesgo de padecerla. Infectio. 2011;15:49-63. https://doi.org/10.1016/S0123-9392(11)70076-5

Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-82. https://doi.org/10.1056/NEJMoa066906

Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409-19. https://doi.org/10.1128/AAC.01657-09

Maldonado NA, Cano LE, De Bedout C, Arbeláez CA, Roncancio G, Tabares AM, et al. Association of clinical and demographic factors in invasive candidiasis caused by fluconazoleresistant Candida species: A study in 15 hospitals, Medellín, Colombia 2010-2011. Diagn Microbiol Infect Dis. 2014;79:280-6. https://doi.org/10.1016/j.diagmicrobio.2014.02.003

Rodríguez-Leguizamón G, Fiori A, Lagrou K, Gaona MA, Ibañéz M, Patarroyo MA, et al. New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogota, Colombia, in ten tertiary care centres: An observational study. BMC Infect Dis. 2015;15:108. https://doi.org/10.1186/s12879-015-0840-0

Cómo citar
1.
Cortés JA, Ruiz JF, Melgarejo-Moreno LN, Lemos EV. Candidemia en Colombia. biomedica [Internet]. 1 de marzo de 2020 [citado 23 de abril de 2024];40(1):195-207. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/4400

Algunos artículos similares:

Publicado
2020-03-01
Sección
Revisión de tema

Métricas

Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas
QR Code